# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.55...
The Phase 2 HARMONIC™ study is designed for never smokers with lung adenocarcinoma with the objective to overcome driver mutati...
Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine le...